291 related articles for article (PubMed ID: 31786838)
1. Current and future targets and therapies in metastatic colorectal cancer.
Dzunic M; Petkovic I; Cvetanovic A; Vrbic S; Pejcic I
J BUON; 2019; 24(5):1785-1792. PubMed ID: 31786838
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and prognosis analysis of surgical treatment for bilateral synchronous multiple primary non-small cell lung cancer.
Chen H; Fu Q; Sun K
J BUON; 2019; 24(6):2245-2252. PubMed ID: 31983090
[TBL] [Abstract][Full Text] [Related]
3. Rationally designed treatment for metastatic colorectal cancer: current drug development strategies.
Spiliopoulou P; Arkenau HT
World J Gastroenterol; 2014 Aug; 20(30):10288-95. PubMed ID: 25132745
[TBL] [Abstract][Full Text] [Related]
4. Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches.
Strickler JH; Wu C; Bekaii-Saab T
Cancer Treat Rev; 2017 Nov; 60():109-119. PubMed ID: 28946014
[TBL] [Abstract][Full Text] [Related]
5. MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.
Stiegelbauer V; Perakis S; Deutsch A; Ling H; Gerger A; Pichler M
World J Gastroenterol; 2014 Sep; 20(33):11727-35. PubMed ID: 25206276
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow.
Pohl M; Schmiegel W
Dig Dis; 2016; 34(5):574-9. PubMed ID: 27332557
[TBL] [Abstract][Full Text] [Related]
7. Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer.
Matos I; Elez E; Capdevila J; Tabernero J
Expert Opin Emerg Drugs; 2016 Sep; 21(3):267-82. PubMed ID: 27578253
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer.
Baek SK; Lee KT; Bae SB; Lee SC
Korean J Intern Med; 2019 Nov; 34(6):1188-1196. PubMed ID: 31346151
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor: pathway, therapies, and pipeline.
Goffin JR; Zbuk K
Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
[TBL] [Abstract][Full Text] [Related]
10. Integrating Biomarkers and Targeted Therapy Into Colorectal Cancer Management.
Lieu CH; Corcoran RB; Overman MJ
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():207-215. PubMed ID: 31099678
[TBL] [Abstract][Full Text] [Related]
11. Personalizing medicine for metastatic colorectal cancer: current developments.
Marques AM; Turner A; de Mello RA
World J Gastroenterol; 2014 Aug; 20(30):10425-31. PubMed ID: 25132758
[TBL] [Abstract][Full Text] [Related]
12. The evolution of biomarkers to guide the treatment of metastatic colorectal cancer.
Davis LE
Am J Manag Care; 2018 Apr; 24(7 Suppl):S107-S117. PubMed ID: 30207665
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond.
Al Bitar S; El-Sabban M; Doughan S; Abou-Kheir W
World J Gastroenterol; 2023 Mar; 29(9):1395-1426. PubMed ID: 36998426
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.
Saridaki Z; Georgoulias V; Souglakos J
World J Gastroenterol; 2010 Mar; 16(10):1177-87. PubMed ID: 20222160
[TBL] [Abstract][Full Text] [Related]
15. Present and future of metastatic colorectal cancer treatment: A review of new candidate targets.
Martini G; Troiani T; Cardone C; Vitiello P; Sforza V; Ciardiello D; Napolitano S; Della Corte CM; Morgillo F; Raucci A; Cuomo A; Selvaggi F; Ciardiello F; Martinelli E
World J Gastroenterol; 2017 Jul; 23(26):4675-4688. PubMed ID: 28765689
[TBL] [Abstract][Full Text] [Related]
16. BRAF in metastatic colorectal cancer: the future starts now.
Orlandi A; Calegari A; Inno A; Berenato R; Caporale M; Niger M; Bossi I; Di Bartolomeo M; de Braud F; Pietrantonio F
Pharmacogenomics; 2015 Dec; 16(18):2069-81. PubMed ID: 26615988
[TBL] [Abstract][Full Text] [Related]
17. Predictive and prognostic markers in the treatment of metastatic colorectal cancer (mCRC): personalized medicine at work.
Stintzing S; Stremitzer S; Sebio A; Lenz HJ
Hematol Oncol Clin North Am; 2015 Feb; 29(1):43-60. PubMed ID: 25475572
[TBL] [Abstract][Full Text] [Related]
18. Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications.
Hanna DL; Lenz HJ
Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1091-108. PubMed ID: 27031164
[TBL] [Abstract][Full Text] [Related]
19. Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory.
Sartore-Bianchi A; Loupakis F; Argilés G; Prager GW
Ann Oncol; 2016 Aug; 27(8):1456-66. PubMed ID: 27154421
[TBL] [Abstract][Full Text] [Related]
20. Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer.
Lee MS; Kopetz S
Clin Colorectal Cancer; 2015 Dec; 14(4):203-18. PubMed ID: 26077270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
